Unicycive Therapeutics, Inc. Common Stock (UNCY) is a publicly traded Healthcare sector company. As of May 21, 2026, UNCY trades at $7.77 with a market cap of $217.61M and a P/E ratio of -4.58. UNCY moved +0.13% today. Year to date, UNCY is +40.22%; over the trailing twelve months it is +29.00%. Its 52-week range spans $3.40 to $11.00. Analyst consensus is strong buy with an average price target of $45.43. Rallies surfaces UNCY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hedge funds tracked by Rallies that own UNCY include Citadel Advisors and Renaissance Technologies. The latest tracked quarter is Mar 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Unicycive Therapeutics, Inc. Common Stock.
| Metric | Value |
|---|---|
| Price | $7.77 |
| Market Cap | $217.61M |
| P/E Ratio | -4.58 |
| EPS | $-1.67 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.00 |
| 52-Week Low | $3.40 |
| Volume | 106 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-26.55M |
| Gross Margin | 0.00% |
7 analysts cover UNCY: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $45.43.